SLC5A2 and type 1 diabetes mellitus: Despite that dapagliflozin, or SGLT2-Is in general, is not yet guideline recommended treatment for type 1 diabetes, mainly due to reports of increased ketoacidosis, it will very possibly be applicable to at least some subgroups of type 1 diabetes individuals in the future (Taylor et al., 2019), constituting a need for more trials on SGLT2-Is in type 1 diabetes.